-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" From Brokerages
Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" From Brokerages
Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) have received an average recommendation of "Buy" from the seven analysts that are covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have covered the stock in the last year is $44.86.
REPL has been the subject of several recent research reports. Piper Sandler reduced their price target on Replimune Group to $43.00 in a research report on Monday, August 22nd. SVB Leerink reduced their price target on Replimune Group from $37.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday.
Get Replimune Group alerts:Institutional Trading of Replimune Group
A number of hedge funds have recently modified their holdings of REPL. Frazier Life Sciences Management L.P. purchased a new stake in shares of Replimune Group in the first quarter worth about $12,171,000. State Street Corp boosted its stake in shares of Replimune Group by 36.6% in the first quarter. State Street Corp now owns 1,712,037 shares of the company's stock worth $29,070,000 after buying an additional 458,420 shares during the last quarter. Bank of Montreal Can purchased a new stake in shares of Replimune Group in the second quarter worth about $3,781,000. Renaissance Technologies LLC boosted its stake in shares of Replimune Group by 352.4% in the first quarter. Renaissance Technologies LLC now owns 211,053 shares of the company's stock worth $3,584,000 after buying an additional 164,400 shares during the last quarter. Finally, Emerald Advisers LLC boosted its stake in shares of Replimune Group by 14.6% in the first quarter. Emerald Advisers LLC now owns 1,134,012 shares of the company's stock worth $19,256,000 after buying an additional 144,054 shares during the last quarter. Hedge funds and other institutional investors own 80.93% of the company's stock.
Replimune Group Trading Down 0.9 %
Shares of NASDAQ REPL opened at $17.12 on Tuesday. The company has a quick ratio of 19.79, a current ratio of 19.79 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $18.80 and a two-hundred day simple moving average of $17.64. The firm has a market cap of $844.14 million, a PE ratio of -6.82 and a beta of 1.90. Replimune Group has a twelve month low of $13.05 and a twelve month high of $35.93.Replimune Group (NASDAQ:REPL – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.15). Analysts expect that Replimune Group will post -3.13 earnings per share for the current fiscal year.
Replimune Group Company Profile
(Get Rating)
Replimune Group, Inc, a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.
Featured Articles
- Get a free copy of the StockNews.com research report on Replimune Group (REPL)
- 3 Stocks Growing Their Businesses for 2023
- China-Based EV Maker BYD Set For Big European, Japanese Expansion
- Is Illumina Still the Gamechanger in Genomics Sequencing?
- Here's What Makes Amazon a Sum-of-All-Parts Commerce Juggernaut
- FedEx Will Deliver Better News in 2023
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) have received an average recommendation of "Buy" from the seven analysts that are covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have covered the stock in the last year is $44.86.
據MarketBeat.com報道,Replimune Group,Inc.(納斯達克代碼:REPL-GET Rating)的股票得到了追蹤該公司的七位分析師的平均買入建議。六位股票研究分析師已將該股評級為買入建議。在去年追蹤該股的經紀商中,12個月目標價的平均水平為44.86美元。
REPL has been the subject of several recent research reports. Piper Sandler reduced their price target on Replimune Group to $43.00 in a research report on Monday, August 22nd. SVB Leerink reduced their price target on Replimune Group from $37.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday.
REPL是最近幾份研究報告的主題。派珀·桑德勒在8月22日週一的一份研究報告中將Replimune Group的目標價下調至43.00美元。SVB Leerink週一在一份研究報告中將Replimune Group的目標價從37.00美元下調至30.00美元,併為該公司設定了“跑贏大盤”的評級。
Institutional Trading of Replimune Group
Replimune集團的機構交易
A number of hedge funds have recently modified their holdings of REPL. Frazier Life Sciences Management L.P. purchased a new stake in shares of Replimune Group in the first quarter worth about $12,171,000. State Street Corp boosted its stake in shares of Replimune Group by 36.6% in the first quarter. State Street Corp now owns 1,712,037 shares of the company's stock worth $29,070,000 after buying an additional 458,420 shares during the last quarter. Bank of Montreal Can purchased a new stake in shares of Replimune Group in the second quarter worth about $3,781,000. Renaissance Technologies LLC boosted its stake in shares of Replimune Group by 352.4% in the first quarter. Renaissance Technologies LLC now owns 211,053 shares of the company's stock worth $3,584,000 after buying an additional 164,400 shares during the last quarter. Finally, Emerald Advisers LLC boosted its stake in shares of Replimune Group by 14.6% in the first quarter. Emerald Advisers LLC now owns 1,134,012 shares of the company's stock worth $19,256,000 after buying an additional 144,054 shares during the last quarter. Hedge funds and other institutional investors own 80.93% of the company's stock.
多家對衝基金最近調整了對REPL的持股。弗雷澤生命科學管理公司在第一季度購買了Replimune Group價值約12,171,000美元的新股。道富集團在第一季度增持了Replimune Group 36.6%的股份。道富銀行目前持有1,712,037股該公司股票,價值29,070,000美元,上一季度又購買了458,420股。蒙特利爾銀行可以在第二季度購買Replimune Group價值約378.1萬美元的新股份。復興科技有限公司在第一季度將其在Replimune集團的股份增加了352.4%。復興科技有限責任公司現在擁有211,053股該公司股票,價值3,584,000美元,在上個季度又購買了164,400股。最後,Emerald Advisers LLC在第一季度將其在Replimune Group的股份增加了14.6%。Emerald Advisers LLC在上個季度額外購買了144,054股後,現在擁有1,134,012股該公司股票,價值19,256,000美元。對衝基金和其他機構投資者持有該公司80.93%的股票。
Replimune Group Trading Down 0.9 %
Replimune Group股價下跌0.9%
Replimune Group (NASDAQ:REPL – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.15). Analysts expect that Replimune Group will post -3.13 earnings per share for the current fiscal year.
複製集團(納斯達克代碼:REPL-GET Rating)最近一次發佈季度收益報告是在8月4日(星期四)。該公司公佈本季度每股收益(0.78美元),低於普遍預期的(0.63美元)和(0.15美元)。分析師預計,Replimune集團本財年的每股收益將為3.13美元。
Replimune Group Company Profile
複製集團公司簡介
(Get Rating)
(獲取評級)
Replimune Group, Inc, a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.
Replimune Group,Inc.是一家生物技術公司,開發治療癌症的溶瘤免疫基因療法。它使用其專有的免疫療法平臺來設計和開發旨在激活免疫系統對抗癌症的候選產品。該公司的主要候選產品是RP1,這是單純皰疹病毒1型的選擇性複製版本,目前正處於針對一系列實體腫瘤的I/II期臨牀試驗,以及針對皮膚鱗狀細胞癌患者的II期臨牀試驗。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Replimune Group (REPL)
- 3 Stocks Growing Their Businesses for 2023
- China-Based EV Maker BYD Set For Big European, Japanese Expansion
- Is Illumina Still the Gamechanger in Genomics Sequencing?
- Here's What Makes Amazon a Sum-of-All-Parts Commerce Juggernaut
- FedEx Will Deliver Better News in 2023
- 免費獲取StockNews.com關於Replimune Group的研究報告(REPL)
- 2023年3只股票實現業務增長
- 中國電動汽車製造商比亞迪將在歐洲和日本大舉擴張
- Illumina仍然是基因組測序中的Gamchanger嗎?
- 以下是亞馬遜成為一個集所有部分於一身的商務巨頭的原因
- 聯邦快遞將在2023年帶來更好的消息
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
接受Replimune Group Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收Replimune Group和相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧